InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Transformation as Berubicin Becomes Subject of Active Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. The company’s pipeline includes Berubicin for the treatment of patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently focused on the development and clinical trials of Berubicin for GBM, as…